Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme

Cancer Chemotherapy and Pharmacology

Volumn 58, Issue 1, 2006, Pages 129-135

  Schott, Anne F ^a,c   Rae, James M ^a,c   Griffith, Kent A ^c   Hayes, Daniel F ^a,c   Sterns, Vered ^b   Baker, Laurence H ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Clinical pharmacology; Erythromycin breath test; Genotype phenotype correlations; Phase I clinical trial

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CYTOCHROME P450 3A5; NAVELBINE; TAXANE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; BREAST CANCER; BREAST METASTASIS; BREATH ANALYSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; DIARRHEA; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ENZYME ACTIVITY; ERYTHROMYCIN BREATH TEST; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HAND FOOT SYNDROME; HUMAN; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY SURFACE AREA; BREAST NEOPLASMS; BREATH TESTS; CYTOCHROME P-450 ENZYME SYSTEM; DEOXYCYTIDINE; ERYTHROMYCIN; FEMALE; GENOTYPE; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; VINBLASTINE;

EID: 33645958840     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0132-2     Document Type: Article

References (29)

1. Baker LH, Vaughn CB, Al-Sarraf M, Reed ML, Vaitkevicius VK (1974) Evaluation of combination vs. sequential cytotoxic chemotherapy in the treatment of advanced breast cancer. Cancer 33:513-518
2. Baker SD, Verweij J, Rowinsky EK, Donehower RC, Schellens JHM, Grochow LB, Sparreboom A (2002) Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. JNCI Cancer Spect 94:1883-1888
3. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T (1999) Multicenter phase II study of capecitabine in paclitaxelrefractory metastatic breast cancer. Journal of Clinical Oncology 17:485-493
4. Cassidy J, Twelves C, Cameron D, Steward W, O'Byrne K, Jodrell DI, Baken L, Goggin T, Jones D, Roos B, Bush E, Wedidekamm E, Reigner B (1999) Bioequivalence to two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemother & Pharmacol 44:453-460
5. Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J, Schuetz E, Lim R, Lim HL, Ong AB, Lee HS (2002) Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 20:3683-3690
6. Hess D, Thurlimann B, Pagani O, Aebi S, Rauch D, Ballabeni P, Rufener B, Castiglione-Gertsch M, Goldhirsch A, Swiss Group of Clinical Cancer Research (2004) Capecitabine and vinorelbine in elderly patients (> or = 65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99). Ann Oncol 15:1760-1765
7. Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH (2000) The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 6:1255-1258
8. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, Koch I, Zibat A, Brockmoller J, Halpert JR, Zanger UM, Wojnowski L (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773-779
9. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF,Flockhart DA (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30-39
10. Kajita J, Kuwabara T, Kobayashi H,Kobayashi S (2000) CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metab Dispos 28:1121-1127
11. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS,Schuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391
12. Lamba JK, Lin YS, Schuetz EG,Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271-1294
13. Leveque D,Jehl F (1996) Clinical pharmacokinetics of vinorelbine. Clin Pharmacokinet 31:184-197
14. Lorusso V, Crucitta E, Silvestris N, Guida M, Misino A, Latorre A,De Lena M (2003) A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer. Clin Breast Cancer 4:138-141
15. Marquet P, Lachatre G, Debord J, Eichler B, Bonnaud F,Nicot G (1992) Pharmacokinetics of vinorelbine in man. Eur J Clin Pharmacol 42:545-547
16. Miles D, von Minckwitz G,Seidman AD (2002) Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist 7(suppl 6):13-19
17. Min DI, Ellingrod VL, Marsh S,McLeod H (2004) CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 26:524-528
18. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S,Leonard R (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812-2823
19. Oshaughnessy JA, Blum J, Moiseyenko V, Jones SE, Miles D, Bell D, Rosso R, Mauriac L, Osterwalder B, Burger HU,Laws S (2001) Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 12:1247-1254
20. Ratain MJ (1998) Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol 16:2297-2298
21. Reigner B, Blesch K,Weidekamm E (2001) Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 40:85-104
22. Sawyer M,Ratain MJ (2001) Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs 19:171-177
23. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK,Wood WC (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21:588-592
24. Smorenburg CH, Sparreboom A, Bontenbal M, Stoter G, Nooter K,Verweij J (2003) Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel.[see comment]. J Clin Oncol 21:197-202
25. VanHeugen J, DeGraeve J, Zorza G, Puozzo C (2001) New sensitive liquid chromatography method coupled with tandem mass spectrometric detection for the clinical analysis of vinorelbine and its metabolites in blood, plasma, urine and faeces. J Chromatogr A 926:11-20
26. Wargin WA,Lucas VS (1994) The clinical pharmacokinetics of vinorelbine (Navelbine). Semin in Oncol 21:21-27
27. Watkins PB (1994) Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4:171-184
28. Welt A, von Minckwitz G, Oberhoff C, Borquez D, Schleucher R, Loibl S, Harstrick A, Kaufmann M, Seeber S,Vanhoefer U (2005) Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. Ann Oncol 16:64-69
29. Wolner E, Domanig E Jr, Elkadi A, Helmer F, Romer P (1968) On a simple relation between blood volume and body surface area. Z Kreislaufforsch 57(1):79-84